Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Purchased by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lifted its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 31.0% in the 1st quarter, Holdings Channel.com reports. The fund owned 63,534 shares of the company’s stock after buying an additional 15,022 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Mirum Pharmaceuticals were worth $1,596,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its holdings in Mirum Pharmaceuticals by 210.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 224,571 shares of the company’s stock valued at $7,096,000 after purchasing an additional 152,287 shares in the last quarter. Federated Hermes Inc. boosted its position in shares of Mirum Pharmaceuticals by 71.2% in the third quarter. Federated Hermes Inc. now owns 20,544 shares of the company’s stock worth $649,000 after buying an additional 8,544 shares during the period. Ardsley Advisory Partners LP acquired a new stake in shares of Mirum Pharmaceuticals in the third quarter valued at about $3,160,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at about $21,014,000. Finally, Polar Capital Holdings Plc lifted its position in Mirum Pharmaceuticals by 27.0% during the 3rd quarter. Polar Capital Holdings Plc now owns 1,175,000 shares of the company’s stock worth $37,130,000 after acquiring an additional 250,000 shares in the last quarter.

Insider Activity at Mirum Pharmaceuticals

In related news, insider Pamela Vig sold 30,559 shares of the company’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $34.00, for a total transaction of $1,039,006.00. Following the completion of the transaction, the insider now directly owns 27,406 shares in the company, valued at approximately $931,804. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Mirum Pharmaceuticals news, Director Saira Ramasastry sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $25.68, for a total value of $128,400.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Pamela Vig sold 30,559 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $34.00, for a total value of $1,039,006.00. Following the transaction, the insider now owns 27,406 shares of the company’s stock, valued at $931,804. The disclosure for this sale can be found here. Insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Stock Performance

MIRM stock opened at $34.19 on Friday. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.14 and a 1-year high of $35.56. The firm has a fifty day moving average price of $26.62 and a two-hundred day moving average price of $27.32. The company has a current ratio of 3.68, a quick ratio of 3.47 and a debt-to-equity ratio of 1.31.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, May 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.14). The business had revenue of $69.22 million during the quarter, compared to the consensus estimate of $69.71 million. Mirum Pharmaceuticals had a negative return on equity of 56.46% and a negative net margin of 69.67%. As a group, analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.66 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on MIRM. Baird R W raised shares of Mirum Pharmaceuticals to a “strong-buy” rating in a research report on Monday, June 17th. HC Wainwright reaffirmed a “buy” rating and set a $66.00 price target on shares of Mirum Pharmaceuticals in a report on Friday. JPMorgan Chase & Co. upped their price objective on shares of Mirum Pharmaceuticals from $31.00 to $39.00 and gave the company an “overweight” rating in a research report on Tuesday, June 18th. JMP Securities lifted their target price on Mirum Pharmaceuticals from $66.00 to $68.00 and gave the stock a “market outperform” rating in a research report on Tuesday, June 18th. Finally, Robert W. Baird increased their target price on Mirum Pharmaceuticals from $34.00 to $39.00 and gave the company an “outperform” rating in a research note on Monday, June 17th. Ten equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $53.64.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.